RxDoctor Payments Data

Jorge Ostolaza Bey, MD

Obstetrics & Gynecology · San Juan, PRNPI 1831165075

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 23 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Merck at 33.3% of the total. Reporting peaked in 2019 at $882 and has fallen 74.3% since, to $227 in 2025.

$1,705in general payments, 2019–2025

Across 23 payments — averaging $74.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$568
  • AbbVie$525
  • Hologic Sales And Service, LLC$281
  • Medtronic$100
  • Roche Diagnostics Corporation$92
  • Smith+Nephew$87
  • plus $53 from 2 others

What the payments were for

  • Food & beverage$1,705100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,705 in reported general payments places this provider in the 85th percentile of 333 obstetrics & gynecology providers in Puerto Rico.

See all obstetrics & gynecology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$3,013
Medicare patients
31
Services billed
51

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Estradiol228$17,198
Risedronate Sodium50$2,769
Estradiol-Norethindrone AcetatEstradiol/Norethindrone Acet12$1,158
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip52$821
Tolterodine Tartrate ErTolterodine Tartrate11$708
ValacyclovirValacyclovir Hcl24$598
SynthroidLevothyroxine Sodium11$542
Ibandronate Sodium23$286
Alendronate Sodium21$164
Fluconazole23$124
Ciprofloxacin Hcl15$77

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSynthroid$525$54211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 333 obstetrics & gynecology providers in Puerto Rico.

Other obstetrics & gynecology in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →